NewAmsterdam Pharma
Latest round
- Series A
Last raised
- Nov 2020
Total raised
- $186M
Investors
- 12
About NewAmsterdam Pharma
V. is dedicated to the development of innovative solutions for cardiovascular diseases.00 mn. The company’s CEO is Michael Davidson, who brings substantial experience in the pharmaceutical sector.NewAmsterdam Pharma focuses on developing treatments for cardiovascular disease (CVD) and lipid disorders, specifically targeting the unmet needs of patients. The company’s flagship product, obicetrapib, is designed to inhibit cholesteryl ester transfer protein (CETP) to lower low-density lipoprotein cholesterol (LDL-C) levels, thereby reducing cardiovascular risk.92 mn. The company's revenue streams derive from direct sales and partnerships with healthcare institutions and pharmaceutical distributors, centered on agreements that facilitate product distribution.00 mn to enhance its product pipeline, focusing on the potential launch of new treatments targeting cardiovascular conditions within the next two years. The company aims to expand its market presence in North America and Europe, along with strategic entry into emerging markets in Asia by 2025.
Who invested in NewAmsterdam Pharma
12 investors across 1 round
See all investors in NewAmsterdam Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 1, 2020
Amount
$186M
Investors
Questions about NewAmsterdam Pharma
Who invested in NewAmsterdam Pharma?
NewAmsterdam Pharma has 12 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NewAmsterdam Pharma raised?
NewAmsterdam Pharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NewAmsterdam Pharma last raise money?
NewAmsterdam Pharma's most recent round on record is a Series A, in Nov 2020.
What does NewAmsterdam Pharma do?
NewAmsterdam Pharma is a biotechnology company.
Where is NewAmsterdam Pharma headquartered?
NewAmsterdam Pharma is headquartered in Naarden, Netherlands.
Which VCs invest in companies like NewAmsterdam Pharma?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at NewAmsterdam Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like NewAmsterdam Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.